Oppenheimer lowered the firm’s price target on Enanta to $17 from $21 and keeps a Perform rating on the shares. Enanta reproted Q1 results and its Phase 2a challenge study of EDP-323 in RSV remains ongoing, with data expected in Q3, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ENTA:
